| __timestamp | BioCryst Pharmaceuticals, Inc. | Eli Lilly and Company |
|---|---|---|
| Wednesday, January 1, 2014 | 122000 | 4932500000 |
| Thursday, January 1, 2015 | 1896000 | 5037200000 |
| Friday, January 1, 2016 | 2699000 | 5654900000 |
| Sunday, January 1, 2017 | 1702000 | 6070200000 |
| Monday, January 1, 2018 | 471000 | 4681700000 |
| Tuesday, January 1, 2019 | 4101000 | 4721200000 |
| Wednesday, January 1, 2020 | 1676000 | 5483300000 |
| Friday, January 1, 2021 | 7264000 | 7312800000 |
| Saturday, January 1, 2022 | 6594000 | 6629800000 |
| Sunday, January 1, 2023 | 4661000 | 7082200000 |
| Monday, January 1, 2024 | 8418299999 |
Unlocking the unknown
In the competitive world of pharmaceuticals, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for two industry players: Eli Lilly and Company and BioCryst Pharmaceuticals, Inc., from 2014 to 2023.
Eli Lilly, a giant in the sector, consistently reported a cost of revenue in the billions, peaking at approximately $7.3 billion in 2021. In contrast, BioCryst, a smaller entity, showed a more modest cost of revenue, reaching its highest at around $7.3 million in the same year.
Over the decade, Eli Lilly's cost of revenue increased by about 43%, while BioCryst's fluctuated significantly, highlighting the challenges smaller companies face in maintaining cost efficiency. This comparison underscores the scale and operational differences between large and small pharmaceutical companies, offering insights into their financial strategies and market positioning.
Analyzing Cost of Revenue: Eli Lilly and Company and GSK plc
Cost Insights: Breaking Down Eli Lilly and Company and Pfizer Inc.'s Expenses
Cost of Revenue Comparison: Eli Lilly and Company vs Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Eli Lilly and Company and BeiGene, Ltd.
Eli Lilly and Company vs Pharming Group N.V.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Eli Lilly and Company and Bausch Health Companies Inc.'s Expenses
Eli Lilly and Company vs BioCryst Pharmaceuticals, Inc.: A Gross Profit Performance Breakdown
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and BioCryst Pharmaceuticals, Inc.
Amgen Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Lantheus Holdings, Inc. vs BioCryst Pharmaceuticals, Inc.